Events
VIVET PRESENTING LEAD PRODUCT, VTX-801, AND PFIC INDICATION VTX-803, AT 2019 INTERNATIONAL LIVER CONGRESS
Vivet Therapeutics will be making a presentation on its lead product
VIVET ATTENDING 3RD ANNUAL GENE THERAPY FOR RARE DISORDERS CONFERENCE IN BOSTON
Jean-Philippe Combal, Vivet Therapeutics’ CEO, will be attending the 3rd Annual Gene Therapy for Rare Disorders conference in Boston (March 26-28 2019).
Vivet presenting during the 2019 Bioprocessing Summit Europe in Lisbon
Vivet Therapeutics’ CEO, Jean-Philippe Combal
Vivet attending DIA Europe 2019 in Vienna on February 5-7
Anne Douar, Chief Development Officer of Vivet Therapeutics
VIVET WILL BE AT THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Jean-Philippe Combal, Vivet Therapeutics’ CEO
Vivet presenting at 2018 Evercore ISI HEALTHCONx in Boston
Vivet Therapeutics CEO, Jean-Philippe Combal
VIVET ATTENDING JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE
Jean-Philippe Combal, Vivet Therapeutics’ CEO, and Thomas Daniel, BD Director, will be hosting 1×1 meetings during Jefferies 2018 London Healthcare Conference on…
VIVET PRESENTING DURING 2018 GENE THERAPY FOR RARE DISORDERS EUROPE CONFERENCE IN LONDON
Anne Douar, Chief Development Officer of Vivet Therapeutics
VIVET THERAPEUTICS ATTENDING 2018 ESGCT 26TH ANNUAL CONGRESS IN LAUSANNE
Vivet Therapeutics will be at the upcoming European Society of Gene And Cell Therapy (ESGCT) 26th annual congress in Lausanne…
Vivet Presenting at 2018 Chardan Gene Therapy conference in New York
Vivet Therapeutics CEO, Jean-Philippe Combal, will be presenting and hosting 1×1 meetings during Chardan Gene Therapy conference in New York on October…
